Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098824 | 1.00 | TDP1 (0.41) | TDP1SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL10829460 | 1.00 | TDP1 (0.41) | TDP1SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL4243856 | 0.76 | CHRNB4 (0.49) | TDP1TSHRCHRNB4CHRNA3 | |
| SCHEMBL726736 | 0.76 | TDP1 (0.41) | TDP1SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL13744161 | 0.74 | SLC6A2 (0.45) | TDP1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL10969259 | 0.74 | SLC6A2 (0.45) | TDP1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL13743615 | 0.74 | SLC6A2 (0.45) | TDP1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9587807 | 0.73 | TDP1 (0.39) | TDP1TSHRCHRNB4CHRNA3 | |
| SCHEMBL10600797 | 0.72 | CYP1A2 (0.39) | TDP1ALDH1A1 | |
| SCHEMBL671115 | 0.72 | TDP1 (0.38) | TDP1TSHRCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022732-B2 | 6-substituted 2,3-dihydro-1,4-benzodioxine, 2-position substituted with carboxy, or (C1 C6)alkoxycarbonyl; diabetes, obesity; 6-[2-(R)-[2-(S)-hydroxy-3-(4-hydroxy-3-methanesulfonamido-phenoxy)propylamino]propyl]-2,3-dihydro-1,4-benzodioxine-2-(R)-carboxylic acid; B3 andrenergic receptor agonist | NISSHIN PHARMA INC. (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040235921-A1 | Propanolamine derivative having 1, 4-Benzodioxane ring | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1426370-A1 | PROPANOLAMINE DERIVATIVE HAVING 1,4 BENZODIOXANE RING | Nisshin Pharma Inc. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235921-A1 | Propanolamine derivative having 1, 4-Benzodioxane ring | ADRA1D, ADRA1A, ADRB1 | TDP1 2659/4885SLC6A2 794/4885SLC6A4 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.